New data released from Spherix Global Insights highlights exciting opportunities in both EU and US for launch brands Hympavzi (Pfizer), Alhemo (Novo Nordisk), Qfitlia (Sanofi) and others, along with ...

Hemophilia A Market Trends The report provides a detailed analysis of the current hemophilia A marketed drugs and late-stage pipeline drugs ...

As multiple companies vie to expand on Alnylam’s success in commercializing RNAi therapeutics, the pioneering company has set ...

CFOTO / Future Publishing via Getty Images A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in one Phase 3 trial.

Sanofi and Regeneron Pharmaceuticals reported mixed results for two late-stage trials of an experimental respiratory drug they are jointly developing, with one study meeting the primary goal and a ...

Regeneron and Sanofi will review the data and discuss it with regulatory authorities to evaluate the next steps. Itepekimab is also being evaluated in other respiratory conditions, including ...

Sanofi and Regeneron said that drug candidate Itepekimab met the primary goal in one of two chronic obstructive pulmonary disease phase 3 studies, but didn't hit the main objective of a second ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the Regeneron-partnered drug failed one of a pair of phase 3 chronic obstructive ...

Regeneron Pharmaceuticals and Sanofi announced that their Phase 3 clinical trial, AERIFY-1, showed a significant 27% reduction in moderate to severe exacerbations of COPD in former smokers treated ...

On this episode of Stock Movers: - Sanofi shares fall following mixed results of its experimental drug for a deadly lung condition. - M&G's shares gain as much as 8.6% to reach the highest since ...

The Hemophilia B treatment landscape is entering a new era, marked by disruptive innovation, curative potential, and renewed global attention. Once viewed as a lifelong burden requiring constant ...